Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Locally Advanced Solid Tumor|Metastatic Solid Tumor|Breast Cancer|Non Small Cell Lung Cancer|Melanoma|Colorectal Cancer
Interventions: DRUG: MSC1936369B (pimasertib)|DRUG: SAR245409 (PI3K and mTOR inhibitor)|DRUG: MSC1936369B (pimasertib)|DRUG: SAR245409 (PI3K and mTOR inhibitor)
Sponsor: EMD Serono
Collaborators: Sanofi